FXN and Friedreich ataxia: Potential therapies aimed at alleviating the transcriptional deficit at the FXN gene in FRDA patients should take into consideration the possibility that elevating transcription levels from the FXN promoter could exacerbate expansion and inhibit therapeutic effectiveness.